CARLSBAD, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced the formation of a human immunodeficiency virus (HIV) Scientific Advisory Board (SAB) with the appointment of seven members, chaired by David D. Ho, M.D. The SAB will provide independent scientific advice and counsel to the Company regarding key decisions relating to the development of drugs to treat HIV.
"Establishing a strong scientific advisory board for our programs is key to our fundamental success," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "The HIV SAB is the first of three planned boards expected to be established during the first half of 2008, and our organization will be made stronger by the counsel of these international HIV physicians."
David D. Ho, MD, (chairman) is the founding Scientific Director and Chief Executive Officer of the Aaron Diamond AIDS Research Center, a world-renowned biomedical research institute. He is also the Irene Diamond Professor at The Rockefeller University. Dr. Ho received his degrees from California Institute of Technology and Harvard Medical School. Dr. Ho has been at the forefront of AIDS research for 27 years, publishing over 350 papers and has received numerous honors and awards for his scientific accomplishments.
Beatriz Grinsztejn, MD, PhD, is the Director of the Instituto de
Pesquisa Clinica Evandro Chagas HIV/AIDS Clinical Research Centre of the
Oswaldo Cruz Foundation (FIOCRUZ) in Rio de Janeiro, Brazil and a faculty
member of the Masters and PhD Degree Program on Clinical Research in
Infectious Diseases at Oswaldo Cruz Foundation. Dr Grinsztejn is the
Principal Investigator of the NIH Clinical Trials Unit at Instituto de
Pesquisa Clinica E
|SOURCE Ardea Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved